32 articles
Delhi High Court reviews whether the Controller of Patents could refuse Fresenius Kabi Ipsum Srl's sugammadex process patent without a separate Section 14 hearing, despite hearing a competitor's…
Array Biopharma Inc. challenged the Deputy Controller of Patents' refusal of its pharmaceutical combination patent for a cancer therapy before the Delhi High Court. Did the Controller's reasoning…
The Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM) has released Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026…
Daewoong Pharmaceutical challenged the Controller's rejection of its crystalline SGLT inhibitor patent before the Delhi High Court. The core question: does improved dissolution and stability satisfy the Section…
Delhi HC affirms rejection of a patent on ZLD process from distillery waste, citing lack of inventive step and application of Section 3(d) of the Patents Act.
Madras High Court backs Amgen on lyophilized peptibody formulations, rejecting Section 3(d), 3(e) and inventive step objections. Grant directed, with claims narrowed to supported sequences.
In a recent ruling, the Delhi High Court overturned the rejection of an anti-cancer patent filed by Taiho Pharmaceutical. The Court highlighted that objections under Section 3(d) must…
The recent judgement of the Calcutta High Court in BASF SE v. Joint Controller of Patents warrants attention for multiple reasons, particularly as it addresses the rejection of…
The Madras High Court overturned a patent refusal in Signal Pharmaceuticals vs. Deputy Controller of Patents, citing a lack of reasoning in the rejection order. The Court observed…
The Madras High Court set aside a patent refusal under section 3d, citing lack of procedural fairness and insufficient reasoning. The Court directed reconsideration, underscoring the necessity of…